Overview

Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis

Status:
Withdrawn
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of AZD1236 in patients with cystic fibrosis (CF) on inflammatory biomarkers in induced sputum, after a treatment period of 4 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca